Guardant Health, Inc.
Guardant Health, Inc.
Your view on GH
Overview
What the company does, where it operates, and who runs it.
About Guardant Health, Inc.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Helmy Eltoukhy
- Headquarters
- 505 Penobscot Drive, Palo Alto, CA, US
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Helmy Eltoukhy
- Headquarters
- 505 Penobscot Drive, Palo Alto, CA, US
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally.
The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.
It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials.
In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus.
Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions.
The company was incorporated in 2011 and is headquartered in Redwood City, California.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Guardant Health, Inc., and the rating behind it. GH last traded at $158.60; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Guardant Health, Inc.. Starting points for Guardant Health, Inc.: EPS -$3.43, beta 1.58 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Guardant Health, Inc.. Guardant Health, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Guardant Health, Inc.. Trailing twelve-month EPS for Guardant Health, Inc. stands at -$3.43. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Guardant Health, Inc.. Guardant Health, Inc. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Guardant Health, Inc. valued side by side against its closest peers. Guardant Health, Inc. is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Guardant Health, Inc., and how their positions are changing. At a $21.28B market value, institutional positions materially move Guardant Health, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Guardant Health, Inc. executives and directors. Shares of Guardant Health, Inc. have traded between $29.91 and $101.57 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Guardant Health, Inc.. Guardant Health, Inc. is a $21.28B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Guardant Health, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Guardant Health, Inc.. Coverage tracks Guardant Health, Inc. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.